Celcuity Inc. (NASDAQ:CELC) Receives Consensus Rating of “Buy” from Brokerages

Shares of Celcuity Inc. (NASDAQ:CELC) have received a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $29.17.

CELC has been the topic of several recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Celcuity in a research report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Celcuity in a research report on Friday, November 15th. Finally, Stifel Nicolaus boosted their price objective on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CELC. Quest Partners LLC boosted its position in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares during the period. Commonwealth Equity Services LLC grew its stake in shares of Celcuity by 9.9% in the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after purchasing an additional 1,500 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Celcuity by 7.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after purchasing an additional 1,600 shares during the period. Acuta Capital Partners LLC raised its position in Celcuity by 3.6% during the 3rd quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock valued at $695,000 after purchasing an additional 1,600 shares during the last quarter. Finally, nVerses Capital LLC purchased a new stake in Celcuity in the 3rd quarter worth approximately $33,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Stock Up 4.4 %

CELC opened at $13.08 on Friday. The business’s fifty day simple moving average is $13.90 and its 200 day simple moving average is $15.35. Celcuity has a 52 week low of $11.51 and a 52 week high of $22.19. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a market cap of $485.66 million, a PE ratio of -5.01 and a beta of 0.74.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.